These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1406 related articles for article (PubMed ID: 17681171)
1. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastaldelli A; Cusi K; Pettiti M; Hardies J; Miyazaki Y; Berria R; Buzzigoli E; Sironi AM; Cersosimo E; Ferrannini E; Defronzo RA Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171 [TBL] [Abstract][Full Text] [Related]
2. [Application of extended hyperinsulinemic euglycemic clamp in the assessment of insulin sensitivity in obese individuals with glucose intolerance]. Bao YQ; Jia WP; Chen L; Lu JX; Zhu M; Lu W; Xiang KA Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):740-4. PubMed ID: 17260458 [TBL] [Abstract][Full Text] [Related]
3. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. Gastaldelli A; Miyazaki Y; Pettiti M; Buzzigoli E; Mahankali S; Ferrannini E; DeFronzo RA J Clin Endocrinol Metab; 2004 Aug; 89(8):3914-21. PubMed ID: 15292327 [TBL] [Abstract][Full Text] [Related]
4. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Kotronen A; Juurinen L; Tiikkainen M; Vehkavaara S; Yki-Järvinen H Gastroenterology; 2008 Jul; 135(1):122-30. PubMed ID: 18474251 [TBL] [Abstract][Full Text] [Related]
5. The effect of pioglitazone on the liver: role of adiponectin. Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306 [TBL] [Abstract][Full Text] [Related]
6. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Boden G; Cheung P; Stein TP; Kresge K; Mozzoli M Am J Physiol Endocrinol Metab; 2002 Jul; 283(1):E12-9. PubMed ID: 12067837 [TBL] [Abstract][Full Text] [Related]
7. Effect of obesity on susceptibility to fatty acid-induced peripheral tissue insulin resistance. Kruszynska YT; Olefsky JM; Frias JP Metabolism; 2003 Feb; 52(2):233-8. PubMed ID: 12601639 [TBL] [Abstract][Full Text] [Related]
8. Body fat distribution modulates insulin sensitivity in post-menopausal overweight and obese women: a MONET study. Tousignant B; Faraj M; Conus F; Garrel D; Brochu M; Rabasa-Lhoret R; Coderre L Int J Obes (Lond); 2008 Nov; 32(11):1626-32. PubMed ID: 18838980 [TBL] [Abstract][Full Text] [Related]
9. Liver fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution. Bozzetto L; Prinster A; Mancini M; Giacco R; De Natale C; Salvatore M; Riccardi G; Rivellese AA; Annuzzi G Eur J Clin Invest; 2011 Jan; 41(1):39-44. PubMed ID: 20825466 [TBL] [Abstract][Full Text] [Related]
10. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657 [TBL] [Abstract][Full Text] [Related]
12. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Bock G; Chittilapilly E; Basu R; Toffolo G; Cobelli C; Chandramouli V; Landau BR; Rizza RA Diabetes; 2007 Jun; 56(6):1703-11. PubMed ID: 17384334 [TBL] [Abstract][Full Text] [Related]
13. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Bonen A; Tandon NN; Glatz JF; Luiken JJ; Heigenhauser GJ Int J Obes (Lond); 2006 Jun; 30(6):877-83. PubMed ID: 16418758 [TBL] [Abstract][Full Text] [Related]
14. Effects of fasting on insulin action and glucose kinetics in lean and obese men and women. Bergman BC; Cornier MA; Horton TJ; Bessesen DH Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1103-11. PubMed ID: 17684102 [TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production. Toft I; Jenssen T Scand J Clin Lab Invest; 2005; 65(4):307-20. PubMed ID: 16076686 [TBL] [Abstract][Full Text] [Related]
16. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518 [TBL] [Abstract][Full Text] [Related]
18. Effect of liver fat on insulin clearance. Kotronen A; Vehkavaara S; Seppälä-Lindroos A; Bergholm R; Yki-Järvinen H Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1709-15. PubMed ID: 17895288 [TBL] [Abstract][Full Text] [Related]
19. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus. da Silva RC; Miranda WL; Chacra AR; Dib SA J Diabetes Complications; 2007; 21(2):84-92. PubMed ID: 17331856 [TBL] [Abstract][Full Text] [Related]
20. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. Jani R; Molina M; Matsuda M; Balas B; Chavez A; DeFronzo RA; Abdul-Ghani M Diabetes Care; 2008 Feb; 31(2):311-5. PubMed ID: 18000182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]